156 related articles for article (PubMed ID: 17286343)
1. Measuring economic outcomes of alcohol treatment using the Economic Form 90.
Bray JW; Zarkin GA; Miller WR; Mitra D; Kivlahan DR; Martin DJ; Couper DJ; Cisler RA
J Stud Alcohol Drugs; 2007 Mar; 68(2):248-55. PubMed ID: 17286343
[TBL] [Abstract][Full Text] [Related]
2. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
[TBL] [Abstract][Full Text] [Related]
3. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Baser O; Chalk M; Rawson R; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
[TBL] [Abstract][Full Text] [Related]
4. The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
Zarkin GA; Bray JW; Aldridge A; Mills M; Cisler RA; Couper D; McKay JR; O'Malley S
Med Care; 2010 May; 48(5):396-401. PubMed ID: 20393362
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
Dunlap LJ; Zarkin GA; Bray JW; Mills M; Kivlahan DR; McKay JR; Latham P; Tonigan JS
Med Care; 2010 Apr; 48(4):306-13. PubMed ID: 20355261
[TBL] [Abstract][Full Text] [Related]
6. Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
[TBL] [Abstract][Full Text] [Related]
7. New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
Doran CM; Fawcett JE; Shakeshaft AP; Shanahan MD; Mattick RP
Med J Aust; 2003 Aug; 179(4):218. PubMed ID: 12914502
[No Abstract] [Full Text] [Related]
8. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
9. The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
Brodtkorb TH; Bell M; Irving AH; Laramée P
CNS Drugs; 2016 Feb; 30(2):163-77. PubMed ID: 26879458
[TBL] [Abstract][Full Text] [Related]
10. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.
Donovan DM; Anton RF; Miller WR; Longabaugh R; Hosking JD; Youngblood M;
J Stud Alcohol Drugs; 2008 Jan; 69(1):5-13. PubMed ID: 18080059
[TBL] [Abstract][Full Text] [Related]
11. A critical review of pharmacoeconomic studies of acamprosate.
Poldrugo F; Haeger DA; Comte S; Walburg J; Palmer AJ
Alcohol Alcohol; 2005; 40(5):422-30. PubMed ID: 15939706
[TBL] [Abstract][Full Text] [Related]
12. Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
Schwappach D; Popova S; Mohapatra S; Patra J; Godinho A; Rehm J
Drug Alcohol Depend; 2012 May; 122(3):165-73. PubMed ID: 21924845
[TBL] [Abstract][Full Text] [Related]
13. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.
Schädlich PK; Brecht JG
Pharmacoeconomics; 1998 Jun; 13(6):719-30. PubMed ID: 10179707
[TBL] [Abstract][Full Text] [Related]
14. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Weiss RD; O'malley SS; Hosking JD; Locastro JS; Swift R;
J Stud Alcohol Drugs; 2008 Nov; 69(6):878-84. PubMed ID: 18925346
[TBL] [Abstract][Full Text] [Related]
15. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management].
Rychlik R; Paschen B; Kirchhoff D; Daniel D; Pfeil T; Kilburg A
Dtsch Med Wochenschr; 2001 Aug; 126(33):899-904. PubMed ID: 11514924
[TBL] [Abstract][Full Text] [Related]
17. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.
Palmer AJ; Neeser K; Weiss C; Brandt A; Comte S; Fox M
Alcohol Alcohol; 2000; 35(5):478-92. PubMed ID: 11022023
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
19. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.
Gueorguieva R; Wu R; Krystal JH; Donovan D; O'Malley SS
Addict Behav; 2013 May; 38(5):2119-27. PubMed ID: 23435273
[TBL] [Abstract][Full Text] [Related]
20. Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Witkiewitz K; Pearson MR; Hallgren KA; Maisto SA; Roos CR; Kirouac M; Wilson AD; Montes KS; Heather N
Addiction; 2017 Dec; 112(12):2112-2121. PubMed ID: 28511286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
